GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short

Group 1 - GSK's stock fell over 6% to 43.60 after the FDA granted a narrower-than-expected approval for its blood cancer treatment, Blenrep [1][2] - Blenrep had previously received accelerated approval in 2020 but was pulled from the market in 2022 after failing its confirmatory study [2] - The company was seeking approval for second-line treatment, which would allow patients to use Blenrep after only one prior therapy [2] Group 2 - Other pharmaceutical stocks are experiencing positive movements, with Sanofi's third-quarter Dupixent sales nearing $5 billion [3] - GSK's ADR shows improved relative strength but remains below benchmark levels [4] - GSK's stock performance is influenced by broader market dynamics, including potential tariffs on pharmaceutical imports [4]